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Case report Paraneoplastic limbic encephalitis presenting as a 
neurological emergency: a case report
Zongqi Xia1,2, Brijesh P Mehta1,2, Allan H Ropper1 and Santosh Kesari*1,3,4
Abstract
Introduction: Paraneoplastic limbic encephalitis remains a challenging clinical diagnosis with poor outcome if it is not 
recognized and treated early in the course of the disease.
Case Presentation: A 65-year-old Caucasian woman presented with generalized tonic-clonic seizures and increasing 
confusion shortly after a lung biopsy that led to the diagnosis of small-cell lung cancer. She had a complicated hospital 
course, and had recurrent respiratory distress due to aspiration pneumonia, and fluctuating mental status and seizures 
that were refractory to anti-epileptic drug treatment. Routine laboratory testing, magnetic resonance imaging of the 
brain, electroencephalogram, lumbar puncture, serum and cerebrospinal fluid tests for paraneoplastic antibodies, and 
chest computed tomography were performed on our patient. The diagnosis was paraneoplastic limbic encephalitis in 
the setting of small-cell lung cancer with positive N-type voltage-gated calcium channel antibody titer. Anti-epileptic 
drugs for seizures, chemotherapy for small-cell lung cancer, and intravenous immunoglobulin and steroids for 
paraneoplastic limbic encephalitis led to a resolution of her seizures and improved her mental status.
Conclusion: Early recognition of paraneoplastic limbic encephalitis and prompt intervention with immune therapies 
at the onset of presentation will probably translate into more favorable neurological outcomes.
Introduction
Paraneoplastic limbic encephalitis (PLE) was established
as a distinct clinical and pathological entity by the British
neuropathologist Corsellis and colleagues in 1968. They
described three patients with bronchial carcinoma who
had developed a subacute onset of memory loss and had
displayed inflammatory and degenerative changes in the
limbic region on post-mortem examination [1]. The cur-
rent hypothesis for the pathogenesis of PLE implicates an
autoimmune process involving antigens shared by tumor
cells and neuronal cells in the mesial temporal and limbic
structures, including cingulated gyrus, orbitofrontal cor-
tex and mamillary bodies [2]. The most frequently associ-
ated neoplasm is small-cell lung cancer (SCLC), followed
by germ cell tumor of the testis, breast cancer, Hodgkin's
lymphoma, thymoma, and immature teratoma of the ova-
ries [3].
Dalmau and colleagues proposed the first criteria for
establishing the diagnosis of PLE in a patient [3]. First, the
clinical presentation must be a subacute onset of neuro-
logical (e.g. short-term memory loss, complex partial or
generalized seizure) and psychiatric symptoms (e.g.
depression, anxiety, irritability, sleep disturbance, para-
noia or hallucination) with an insidious course. Second,
neuropsychiatric symptoms must often precede the rec-
ognition of an underlying malignancy by up to four years,
with a mean latency of three to five months. Third, the
diagnostic evaluation must exclude other complications
of cancer that might also cause limbic dysfunction (e.g.
brain metastasis, metabolic and nutritional deficits, and
adverse effects of chemotherapy or radiation therapy).
Finally, the diagnostic evaluation should also reveal at
least one of the following supporting evidences: (1)
inflammatory changes in the cerebrospinal fluid (CSF),
such as mild to moderate lymphocytic pleocytosis with
fewer than 100 cells, mildly elevated proteins of <150 g/L
with a high immunoglobulin G (IgG) index and the pres-
ence of oligoclonal IgG bands, but without any malignant
cells in cytology; (2) one or both temporal lobe abnormal-
ities on MRI such as hyperintense signals on T2-weighted
or fluid-attenuated inversion recovery (FLAIR)
sequences, atrophic temporal-limbic structures on T1-
weighted images, typically without contrast-enhance-
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ment in the brain parenchyma or leptomeninges; (3) focal
slowing or epileptiform activity in one or both temporal
lobes on electroencephalography (EEG). Although tem-
poral lobe seizures or status epilepticus is non-specific,
its recognition is crucial to symptomatic management
and patient stabilization. PLE is rare in patients with both
normal EEG and normal brain MRI [4].
The list of differential diagnosis with similar clinical
presentation includes viral encephalitis (e.g. herpes sim-
plex virus [HSV]), lupus cerebritis, toxic and metabolic
encephalopathies, multiple sclerosis, Hashimoto's
encephalopathy, Wernicke's encephalopathy, neurosyphi-
lis, primary vasculitis of the central nervous system, and
leptomeningeal involvement of malignancy [2].
There is no evidence-based recommendation for the
treatment of PLE. Current opinion favored applying a
two-pronged approach for our patient with PLE, using a
combination of tumor removal to eliminate the source of
paraneoplastic onconeuronal antigens, and immune ther-
apy (e.g. intravenous steroid, intravenous immunoglobu-
lin (IVIG), or plasma exchange) to prevent further
immune-mediated neuronal injury [2,5]. The prognosis
for recovery in patients with PLE is poor if immune ther-
apy is administered without concomitant treatment of
the underlying malignancy [3]. Prompt initiation of
immune therapy is probably associated with an improved
overall outcome.
The prognosis is dependent upon the type of associated
paraneoplastic onconeuronal antigen. In general, cyto-
toxic T-cell mediated process associated with intracellu-
lar antigens (e.g. Hu) is less responsive to the
aforementioned two-pronged approach of tumor removal
and immune therapy than immune process associated
with cell surface antigens, and thus carries a worse neuro-
logical outcome [6].
Case Presentation
A 65-year-old, right-handed Caucasian woman was
transferred from a local hospital to our neurological
intensive care unit (NICU) after a witnessed generalized
tonic-clonic seizure. She had hypertension, diabetes mel-
litus, dyslipidemia, chronic obstructive pulmonary disor-
der, a history of heavy cigarette smoking and a long-
standing but well-controlled bipolar disorder. Three
weeks before the seizure, biopsy of a right hilar mass via
mediastinoscopy confirmed the diagnosis of SCLC.
Treatment for the cancer had not been initiated. Shortly
after the biopsy, her family found her to be intermittently
confused. Over the following two days, she developed
fever, dizziness, vomiting, poor appetite and progressive
shortness of breath. Confusion worsened to the point that
she could no longer recognize her family and became
non-interactive. She remained lethargic and confused
despite treatment with ceftriaxone and azithromycin for
right lower lobe pneumonia. Investigations and results at
the local hospital included: (1) CSF analysis showed 28
white blood cells with 99% lymphocytes, glucose 122 g/L,
protein 36 g/L, no organisms on Gram stain and no
growth from bacterial culture; (2) MRI of the brain
showed T2 and FLAIR hyperintensities in both mesial
temporal regions without contrast enhancement, diffu-
sion or susceptibility changes; (3) EEG demonstrated
background slowing with focal sharp and slow discharges
in the right mid-temporal and right posterior temporal
region. Empiric treatment with intravenous acyclovir was
initiated while HSV polymerase chain reaction (PCR)
study from CSF was sent for analysis. On her seventh day
at the local hospital, she was observed having a general-
ized tonic-clonic seizure for which she received intrave-
nous fosphenytoin. She was intubated and transferred to
our NICU.
On examination, she was unresponsive to verbal or
noxious stimuli. Her pupils were restricted from previous
cataract procedures. There was no gaze preference. Cor-
neal, vestibular-ocular and gag reflexes were intact. Her
tone was normal. She made no purposeful withdrawal on
the left side. A Babinski maneuver elicited a plantar
response from both feet.
She had a second, brief, witnessed generalized tonic-
clonic seizure with left gaze deviation and left head turn-
ing. An EEG demonstrated electrographic seizures con-
sisting of bilateral independent periodic lateralized
epileptiform discharges (bi-PLEDs) in both temporal
lobes with right-sided predominance (Figure 1). Intrave-
nous lorazepam was given and phenytoin was reloaded.
Levetiracetam and topiramate were subsequently added
in increasing doses (up to maximum dosages) to treat
persistent electrographic seizures. Repeat CSF analysis
again demonstrated mild pleocytosis with lymphocytic
predominance (23 white blood cells with 94% lympho-
cytes) but was otherwise normal. CSF cytology did not
show any malignant cells. Empiric treatment with acyclo-
vir for HSV encephalitis continued until a second nega-
tive CSF HSV PCR returned. Epstein-Barr virus (EBV),
cytomegalovirus (CMV), varicella zoster virus (VZV) and
human herpesvirus 6 (HHV-6) were all negative. Repeat
MRI of the brain showed T2-FLAIR hyperintensities in
both mesial temporal lobes without restricted diffusion
or post-gadolinium enhancement (Figures 2A-C). Chest
X-ray showed post-obstructive pneumonia in the right
lower lobe with collapse of the right middle and upper
lobes due to compressive atelectasis from the lung cancer
( F i g u r e  2 D ) .  C o m p u t e d  t o m o g r a p h y  ( C T )  s c a n  o f  t h e
chest demonstrated mediastinal and hilar lymphadenop-
athy and pleural effusion in addition to a loculated right
lower lobe (Figure 2E). Her lung cancer was not amenable
to resection. She continued to receive broad-spectrumXia et al. Journal of Medical Case Reports 2010, 4:95
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antibiotics for pneumonia, and chemotherapy for SCLC
with carboplatin and etoposide was commenced.
Serum contained markedly elevated anti-N-type volt-
age-gated calcium channel (VGCC) antibody titer of 0.42
nmol/L (normal value < 0.03) and mildly elevated anti-P/
Q-type VGCC antibody titer of 0.04 nmol/L (normal
value < 0.02). No other paraneoplastic antibody (includ-
ing binding, ganglionic and striational acetycholine [Ach]
receptor antibodies, Purjinke cell antibodies type 1
[PCA-1 or anti-Yo], PCA-2, PCA-Tr [anti-Tr, immune
response marker for Hodgkin's lymphoma], anti-neu-
ronal nuclear antibodies type 1 [ANNA-1 or aniti-Hu],
ANNA-2 [anti-Ri], ANNA-3, anti-Ma1, anti-Ta, collapsin
response-mediator protein-5 [CRMP-5 or CV2], amph-
iphysin, anti-glial/neuronal nuclear antibody, Type 1
AGNA-1) was detected. Voltage-gated potassium chan-
nel (VGKC), N-methyl-D-aspartate receptor (NMDAR)
and glutamic acid decarboxylase (GAD) antibodies were
not sent. Our patient received IVIG (0.4 mg/kg daily for
five days) and 1 g of Solu-medrol (methylprednisolone)
daily for three days, followed by tapering doses of predni-
sone over four weeks. Long-term monitoring (LTM) EEG
showed gradual resolution of epileptiform activities only
after initiation of immune therapy, despite being on mul-
tiple anti-epileptic drugs.
Two months after the onset of her neurological illness,
she was following commands and had become conversant
but she still displayed cognitive impairment and still suf-
fered episodes of delirium. Our patient had multiple sub-
sequent hospitalizations for aspiration pneumonia and
seizures that were refractory to anti-epileptic drug adjust-
ments and only responsive to IVIG and steroids on a
monthly basis. MRI six months later showed resolution of
T2-FLAIR hyperintensities (Figure 2F). However, she
c o n t i n u e d  t o  h a v e  s e v e r e  s h o r t - t e r m  m e m o r y  d e f i c i t s .
She died eight months after the initial presentation due to
progressive lung cancer.
Figure 1 Electroencephalography (low frequency 10 Hz, high frequency 70 Hz) showing epileptiform activity is comprised of bilateral in-
dependent periodic lateralized epileptiform discharges (bi-PLEDs) in both temporal lobes with a right-sided predominance (arrows).Xia et al. Journal of Medical Case Reports 2010, 4:95
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Discussion
Although the association between PLE and auto-antibod-
ies against neuronal antigens (nuclear, cytoplasmic or ion
channel) is well-known [3], there has been no definitive
proof of any specific cause-effect relationship between
the presence of antibodies and the development of clini-
cal syndrome [7]. Onconeuronal auto-antibodies have
been found in cancer patients without apparent paraneo-
plastic neurological syndrome [8], and they have been
undetectable in a subpopulation of symptomatic patients
[9]. Since onconeuronal auto-antibodies in PLE are best
considered as biomarkers rather than as a proof of patho-
genesis, the absence of paraneoplastic neuronal antibod-
ies does not necessarily argue against PLE [4]. While the
P/Q-type VGCC auto-antibody is known to be associated
with Lambert-Eaton myasthenic syndrome, cerebellar
degeneration and SCLC [10,11], the association with the
N-type VGCC has not been well-described. In this case,
the high titer of the N-type VGCC antibody in the setting
of SCLC is insufficient to prove the auto-antibody was
the cause of the neurological decline.
Although PLE is rare (with a slightly greater predomi-
nance among women), the disease is under-reported due
to the difficulty in establishing the diagnosis [12]. Several
factors render the diagnosis of PLE challenging. First,
many other cancer-related complications, including brain
metastases, toxic and metabolic encephalopathies, and
adverse effects of cancer therapy, may have similar insidi-
ous neuropsychiatric presentations. Second, diseases
other than PLE, particularly those of an infectious etiol-
ogy such as HSV, share similar initial clinical features to
PLE. Third, there is no "gold standard" method of estab-
lishing a diagnosis. The pathological findings of neuronal
loss, perivascular inflammatory infiltrates, microglial
activation, and reactive astrocytosis in the temporal and
limbic structures are non-specific and do not establish a
paraneoplastic etiology.
Figure 2 Magnetic resonance imaging (MRI) of the brain. (A) T1-post-gadolinium sequence with no enhancement. (B) T2-fluid-attenuated inver-
sion recovery (FLAIR) sequence with hyperintensities in both mesial temporal lobes (arrow). (C) Diffusion-weighted images with T2 shine-through in 
the right temporal lobe and hippocampus (arrow). (D) Chest X-ray with right lower lobe infiltrates consistent with post-obstructive pneumonia (long 
arrow), complete opacity of the right middle and upper lobes due to atelectasis from small-cell lung cancer (short arrows). (E) Chest computed to-
mography scan with contrast of mediastinal and hilar lymphadenopathy (short arrows) and a loculated right lower lobe pleural effusion (long arrows). 
(F) MRI of the brain 6 months after initial neurological presentation with temporal horn enlargement (short arrow), hippocampal atrophy (long arrow) 
and resolution of T2-FLAIR hyperintensities.Xia et al. Journal of Medical Case Reports 2010, 4:95
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The unusual feature of our case of PLE is the clinical
course of neuropsychiatric manifestation in relation to
the discovery of the underlying malignancy. In a recent
case report, a patient with refractory seizure, in the set-
ting of testicular cancer and anti-Ma-2 antibodies,
s h o w ed  n o  ev i d e n c e  o f  m e m o ry  d e c l i n e  o r  p s y c h i a t r i c
symptoms prior to presentation [13]. Likewise in our
case, there was no history of neuropsychiatric manifesta-
tion prior to the biopsy that led to the eventual diagnosis
of SCLC. In fact, our patient presented with altered men-
tal status and subsequent seizures only after the biopsy.
This raised the intriguing possibility that perturbation of
the tumor tissues might have accelerated an immune
response to onconeuronal auto-antigens and inflamma-
tion-mediated neuronal injury. The pneumonia might
have contributed initially, but even after treatment of the
pneumonia, the neurological status of our patient contin-
ued to decline. Otherwise, the clinical picture in our case
is consistent with the diagnosis of PLE, which is addition-
ally supported by results from the CSF, MRI, EEG and
paraneoplastic antibody studies.
In the early stages of the disease, PLE and HSV enceph-
alitis share not only similar clinical presentation but also
comparable MRI features. However, MRIs of patients
with HSV encephalitis typically demonstrate more prom-
inent gyral enhancement on T1-weighted post-gadolin-
ium sequences. They also demonstrate more significant
mass effects from cytotoxic edema on T2-weighted
sequences, and more evident hemorrhages on suscepti-
bility sequences [3,4]. Additionally, the presence of dis-
proportionally elevated red blood cells in the CSF further
raises the suspicion for HSV encephalitis. One caveat is
that PCR for HSV from the CSF could be negative if the
CSF is obtained within the first 72 hours after the onset of
neurological symptoms, despite the otherwise high sensi-
tivity and specificity of this method of detection [14].
In our case, HSV encephalitis clearly ranked high in the
initial differential diagnosis, given the patient's seizure in
the setting of fever and her history of altered mental sta-
tus. In retrospect, post-obstructive pneumonia was the
likely cause of the fever. Nevertheless, HSV encephalitis
was not an unreasonable initial working diagnosis of
equal possibility to PLE.
The median survival time after diagnosis of PLE ranges
between 22 and 43 months [2]. The overall poor outcome
of PLE likely stems from both the delay in recognition
and treatment, and the resulting immune-mediated neu-
ronal injury. Thus, we advocate the initiation of immune
therapy as soon as a clinical suspicion of PLE is raised.
Even with prompt treatment, irreversible neuronal dam-
age and neuropsychiatric complications in our patient
might have been unavoidable due to the delayed thera-
peutic effect of immune therapy in disorders of the cen-
tral nervous system [7]. Long-term complications include
recurrent seizures, anterograde amnesia, cognitive
impairments and chronic progressive encephalopathy
with associated cerebral atrophy, particularly involving
the mesial temporal and limbic structures [15].
Early immune treatment is particularly important with
the emergence of rituximab, an anti-CD20 antibody that
depletes B-cells and potentially the source of paraneo-
plastic antibody production [16]. B-cells cross the blood-
brain barrier and intrathecal production of antibodies
correlates with clinical severity in paraneoplastic disease
[17]. There is early evidence that rituximab is safe and
may improve neurological outcomes, as seen in adjunct
therapy in children with paraneoplastic opsoclonus-myo-
clonus syndrome [17], as well as in paraneoplastic syn-
dromes related to intracellular auto-antigens [18]. Since
these studies are small and non-randomized, we cannot
make conclusive statements about the role of rituximab
in the management of paraneoplastic diseases.
The greatest challenge in the management of patients
with PLE is to promptly deliver immune therapy and can-
cer treatment. With SCLC, the definitive treatment for
cancer is chemotherapy, since surgery rarely plays a role.
To undergo chemotherapy, patients have to be medically
stable. In the case of our patient, chemotherapy for SCLC
did not commence until her pneumonia was better con-
trolled. The predicament was that the pneumonia of our
patient, which delayed chemotherapy in the first place,
was probably the result of a post-obstructive etiology
from the tumor burden of the lung cancer itself.
Another instructive lesson in our case is that immune
therapy should have been initiated empirically at the
onset of the presentation and continued until PLE could
be excluded. This would be analogous to the approach of
initiating empiric treatment with acyclovir until HSV
encephalitis is definitively excluded. In both situations,
the delay in treatment while waiting for supporting diag-
nostic studies, HSV PCR and paraneoplastic panels,
respectively, could potentially lead to devastating neuro-
logical outcomes. The benefit of empiric treatment with
acyclovir outweighs the risk of not pursuing therapy
while awaiting the results of diagnostic tests. Likewise, we
recommend that in most patients the risks of immune
therapy (IVIG or plasma exchange, steroids) are low
enough to warrant early empiric intervention if there is
sufficient clinical suspicion of PLE. We recommend the
following tests before proceeding with empirical therapy
for PLE: MRI of the brain, CSF analysis for bacterial and
viral agents (in particular HSV PCR), measurement of
ammonia levels and thyroid-stimulating hormone (TSH),
a metabolic and electrolyte panel, EEG, and a paraneo-
plastic panel of both blood and CSF.
Conclusion
This case illustrates the complex diagnostic and treat-
ment decisions that clinicians will need to make in a rela-
tively short period of time. We wait far too often for the
results of diagnostic testing and delay the definitive treat-
ment for PLE. This causes patients to suffer devastatingXia et al. Journal of Medical Case Reports 2010, 4:95
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neurological sequalae. In the setting of known cancer, the
decision to treat patients for paraneoplastic neurological
syndrome should be empirically considered. Early inter-
vention with immune therapies in patients at the onset of
presentation will probably translate into more favorable
neurological outcomes, but definitive practice parame-
ters will have to be developed judiciously, especially with
the development of potentially more effective targeted
therapies such as rituximab.
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